Cantex is engaged in developing novel, safer and more effective cancer treatments with potent anticancer activity and reduced side effects that can directly treat the disease while significantly improving the quality of patients’ lives.

Cantex’s ODSH and DSF-C development programs harness known therapies to addresses major unmet medical needs representing high-value market opportunities.

Latest News


Cantex unveils advanced pipeline consisting of multiple Phase II ready programs. Clinical and regulatory milestones expected in 2014, 2015 and 2016.